Get all your news in one place.

100’s of premium titles.
One app.

Get all your news in one place.

100’s of premium titles. One news app.

The Latest Breaking News from Evolus

Evolus Reaches 80-Plus Relative Strength Rating Benchmark

Evolus sees its Relative Strength Rating move into the 80-plus level.

Investors Business Daily

IBD Rating Upgrades: Evolus Flashes Improved Price Strength

IBD Rating Upgrades: Evolus Flashes Improved Price Strength

A Relative Strength Rating upgrade for Evolus shows improving technical performance. Will it continue?

Investors Business Daily

Stocks With Rising Relative Price Strength: Evolus

Stocks With Rising Relative Price Strength: Evolus

Evolus sees its Relative Strength Rating enter the 80-plus level.

Investors Business Daily

From analysis to the latest developments in health,
read the most diverse news in one place.

inkl

Evolus Sees IBD RS Rating Rise To 75

Evolus shows improving price performance, earning an upgrade to its IBD Relative Strength Rating

Investors Business Daily

Evolus, An AbbVie And Botox Rival, Just Hit The Stratosphere — Here's Why

Shares of Evolus made a doubly bullish move Tuesday on a strong preliminary fourth-quarter report and guidance for 2025.

Investors Business Daily

Evolus, A Medical Aesthetics Player, Becomes Profitable — Two Quarters Early

Shares of Evolus jumped Thursday after the medical aesthetics company notched its first-ever operating income — two quarters early.

Investors Business Daily

Needham Is Bullish On This Botox Equivalent Aesthetics Company

Needham initiated coverage on Evolus Inc (NASDAQ:EOLS) with a price target of $18.00 (43% upside) and a Buy rating. Evolus is a pure-play aesthetics company focused on growing the presence of Jeuveau, its new neurotoxin product, in the approximately $3 billion global wrinkle treatment market. Jeuveau is a prescription medicine injected into muscles to improve…

inkl

Read news from The Economist, FT, and more,
with one subscription

Evolus's Return On Capital Employed Overview

Evolus's Return On Capital Employed Overview

According to data from Benzinga Pro, during Q1, Evolus's (NASDAQ:EOLS) reported sales totaled $33.91 million. Despite a 3.72% increase in earnings, the company posted a loss of $17.50 million.

Benzinga's Top Ratings Upgrades, Downgrades For May 13, 2022

Benzinga's Top Ratings Upgrades, Downgrades For May 13, 2022

Benzinga's Top Ratings Upgrades, Downgrades For May 12, 2022

Benzinga's Top Ratings Upgrades, Downgrades For May 12, 2022

Evolus: Q1 Earnings Insights

Evolus: Q1 Earnings Insights

Evolus (NASDAQ:EOLS) reported its Q1 earnings results on Tuesday, May 10, 2022 at 04:05 PM. Here's what investors need to know about the announcement. Earnings Evolus beat estimated earnings by 6.06%, reporting an EPS of $-0.31 versus an estimate of $-0.33.

Evolus's Return On Capital Employed Insights

Evolus's Return On Capital Employed Insights

According to Benzinga Pro data, during Q4, Evolus (NASDAQ:EOLS) posted sales of $34.66 million. Earnings were up 6.46%, but Evolus still reported an overall loss of $18.18 million.

Evolus Reports Narrower Q4 Loss, CFO Retires, Reaffirms FY22 Outlook

Evolus Reports Narrower Q4 Loss, CFO Retires, Reaffirms FY22 Outlook

Evolus Inc's (NASDAQ: EOLS)

Recap: Evolus Q4 Earnings

Recap: Evolus Q4 Earnings

Evolus (NASDAQ:EOLS) reported its Q4 earnings results on Thursday, March 3, 2022 at 04:05 PM. Here's what investors need to know about the announcement. Earnings Evolus missed estimated earnings by 73.68%, reporting an EPS of $-0.33 versus an estimate of $-0.19.

Get all your
news in one place.

100’s of premium titles.
One news app.

A Preview Of Evolus's Earnings

Evolus (NASDAQ:EOLS) is set to give its latest quarterly earnings report on Thursday, 2022-03-03. Here's what investors need to know before the announcement. Analysts estimate that Evolus will report an earnings per share (EPS) of $-0.19.

Evolus Expects Q4 FY21 Sales Better Than Anticipated, Issues FY22 Guidance

Evolus Inc (NASDAQ: EOLS) has posted

People

From analysis to the latest developments in health,
read the most diverse news in one place.

inkl

Organisations

Investor Business Daily

American Express

B of A Securities

inkl

Read news from The Economist, FT, and more,
with one subscription

Places

304,345 stories

Fourteen days free

Download the app

One app. One membership.
100+ trusted global sources.

Download on the AppStore

Get it on Google Play